Study of ensartinib for advanced ALK-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IIIb or stage IV NSCLC (confirmed by biopsy or cell test).
- Your tumor tests positive for ALK using one of these tests: FISH, IHC, RT-PCR, or NGS.
- Your cancer has progressed during or after prior ALK-TKI treatment.
- You feel able to do daily activities at level 0 to 2 (ECOG performance status) and are expected to live more than 3 months.
- You need (or can receive) radiotherapy, such as for bone, lung, or adrenal metastases.
- You can have required blood/urine lab testing and agree to effective birth control (or abstain) during the study and for 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called ensartinib after you finish chemotherapy and radiation for stage III ALK-positive lung cancer. It may help keep the cancer from coming back.
This study tests the drug ensartinib, given before surgery, for people with ALK-positive lung cancer. Taking ensartinib first might shrink the tumor and make surgery more effective.
This study looks at how well alectinib works when given after surgery to people with early-stage ALK-positive non-small cell lung cancer. It aims to understand real-world outcomes for patients who take this targeted therapy as their first treatment after surgery.
This trial tests whether taking ensartinib after surgery can lower the chance of lung cancer coming back in people whose tumors have a specific genetic change called ALK. The study uses a blood test called MRD to guide treatment.
This trial provides access to ensartinib, an oral medication that targets a specific genetic change in non-small cell lung cancer (NSCLC). It is for people who cannot join other clinical trials for ensartinib and may help control the cancer.
This trial tests whether taking a pill called ensartinib after surgery can help prevent early stage lung cancer from coming back. It is for people whose tumors have a specific gene change called ALK and who have high-risk features.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.